Pharmaceutical manufacturer communications about research on unapproved uses that has not undergone peer review and publication raises transparency and monitoring concerns, US FDA Commissioner Robert Califf suggested Nov. 9.
During the first day of a widely anticipated two-day hearing on manufacturer communications, representatives from the biopharmaceutical and medical device industries urged FDA to modernize its regulations so that companies can share truthful, non-misleading information about unapproved uses, or